"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Editorial
peer-reviewed

On the Horizon: The Synthetic Opioid U-49900



Abstract

Synthetic opioid use continues to be a problem in the United States. New designer opioids continue to be released as "research chemicals" by vendors, leading to widespread use and potentially devastating consequences. U-49900 is a new synthetic opioid with limited clinical data available. Herein, we provide an overview of U-49900, the anecdotal accounts of U-49900 use that clinicians need to be made aware of, and a call for the federal government to take immediate action in curtailing the use of U-49900.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Editorial
peer-reviewed

On the Horizon: The Synthetic Opioid U-49900


Author Information

Saeed K. Alzghari

Gulfstream Genomics, Gulfstream Diagnostics

Zubair M. Amin Corresponding Author

Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

Sophie Chau

School of Pharmacy, Texas Tech University Health Sciences Center

Steven W. Fleming

Reference Health Laboratories, Gulfstream Diagnostics

Kevin Cho

Reference Health Laboratories, Gulfstream Diagnostics

Victor Fung

Department of Emergency Medicine, Parkland Health and Hospital System, Dallas Texas


Ethics Statement and Conflict of Interest Disclosures

Conflicts of interest: The authors have declared the following conflicts of interest: Financial relationships: Saeed K. Alzghari, Steven W. Fleming, and Kevin Cho declare(s) employment from Gulfstream Diagnostics.


Editorial
peer-reviewed

On the Horizon: The Synthetic Opioid U-49900


Figures etc.

Share
Editorial
peer-reviewed

On the Horizon: The Synthetic Opioid U-49900

  • Author Information
    Saeed K. Alzghari

    Gulfstream Genomics, Gulfstream Diagnostics

    Zubair M. Amin Corresponding Author

    Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

    Sophie Chau

    School of Pharmacy, Texas Tech University Health Sciences Center

    Steven W. Fleming

    Reference Health Laboratories, Gulfstream Diagnostics

    Kevin Cho

    Reference Health Laboratories, Gulfstream Diagnostics

    Victor Fung

    Department of Emergency Medicine, Parkland Health and Hospital System, Dallas Texas


    Ethics Statement and Conflict of Interest Disclosures

    Conflicts of interest: The authors have declared the following conflicts of interest: Financial relationships: Saeed K. Alzghari, Steven W. Fleming, and Kevin Cho declare(s) employment from Gulfstream Diagnostics.

    Acknowledgements


    Article Information

    Published: September 12, 2017

    DOI

    10.7759/cureus.1679

    Cite this article as:

    Alzghari S K, Amin Z M, Chau S, et al. (September 12, 2017) On the Horizon: The Synthetic Opioid U-49900. Cureus 9(9): e1679. doi:10.7759/cureus.1679

    Publication history

    Received by Cureus: August 30, 2017
    Peer review began: September 07, 2017
    Peer review concluded: September 09, 2017
    Published: September 12, 2017

    Copyright

    © Copyright 2017
    Alzghari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Synthetic opioid use continues to be a problem in the United States. New designer opioids continue to be released as "research chemicals" by vendors, leading to widespread use and potentially devastating consequences. U-49900 is a new synthetic opioid with limited clinical data available. Herein, we provide an overview of U-49900, the anecdotal accounts of U-49900 use that clinicians need to be made aware of, and a call for the federal government to take immediate action in curtailing the use of U-49900.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Saeed K. Alzghari, M.S., M.B.A. (HOM), Pharm.D., BCPS

Gulfstream Genomics, Gulfstream Diagnostics

Zubair M. Amin, Pharmacy Student

Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

For correspondence:
z_amin@u.pacific.edu

Sophie Chau

School of Pharmacy, Texas Tech University Health Sciences Center

Steven W. Fleming, M.Sc.

Reference Health Laboratories, Gulfstream Diagnostics

Kevin Cho

Reference Health Laboratories, Gulfstream Diagnostics

Victor Fung, B.Sc.

Department of Emergency Medicine, Parkland Health and Hospital System, Dallas Texas

Saeed K. Alzghari, M.S., M.B.A. (HOM), Pharm.D., BCPS

Gulfstream Genomics, Gulfstream Diagnostics

Zubair M. Amin, Pharmacy Student

Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific

For correspondence:
z_amin@u.pacific.edu

Sophie Chau

School of Pharmacy, Texas Tech University Health Sciences Center

Steven W. Fleming, M.Sc.

Reference Health Laboratories, Gulfstream Diagnostics

Kevin Cho

Reference Health Laboratories, Gulfstream Diagnostics

Victor Fung, B.Sc.

Department of Emergency Medicine, Parkland Health and Hospital System, Dallas Texas